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Abstract
Purpose In head and neck cancer (HNC) various treatment
strategies have been developed to improve outcome, but
selecting patients for these intensified treatments remains
difficult. Therefore, identification of novel pretreatment
assays to predict outcome is of interest. In HNC there are
indications that pretreatment tumour
18F-fluorodeoxyglu-
cose (FDG) uptake may be an independent prognostic
factor. The aim of this study was to assess the prognostic
value of FDG uptake and CT-based and FDG PET-based
primary tumour volume measurements in patients with
HNC treated with (chemo)radiotherapy.
Methods A total of 77 patients with stage II–IV HNC who
were eligible for definitive (chemo)radiotherapy underwent
coregistered pretreatment CT and FDG PET. The gross
tumour volume of the primary tumour was determined on
the CT (GTVCT) and FDG PET scans. Five PET segmen-
tation methods were applied: interpreting FDG PET
visually (PETVIS), applying an isocontour at a standardized
uptake value (SUV) of 2.5 (PET2.5), using fixed thresholds
of 40% and 50% (PET40%, PET50%) of the maximum
intratumoral FDG activity (SUVMAX) and applying an
adaptive threshold based on the signal-to-background
(PETSBR). Mean FDG uptake for each PET-based volume
was recorded (SUVmean). Subsequently, to determine the
metabolic volume, the integrated SUV was calculated as the
product of PET-based volume and SUVmean. All these
variables were analysed as potential predictors of local
control (LC), regional recurrence-free survival (RRFS),
distant metastasis-free survival (DMFS), disease-free sur-
vival (DFS) and overall survival (OS).
Results In oral cavity/oropharynx tumours PETVIS was the
only volume-based method able to predict LC. Both
PETVIS and GTVCT were able to predict DMFS, DFS and
OS in these subsites. Integrated SUVs were associated with
LC, DMFS, DFS and OS, while SUVmean and SUVMAX
were not. In hypopharyngeal/laryngeal tumours none of the
variables was associated with outcome.
Conclusion There is no role yet for pretreatment FDG PET
as a predictor of (chemo)radiotherapy outcome in HNC in
daily routine. However, this potential application needs
further exploration, focusing both on FDG PET-based
primary tumour volume, integrated SUV and SUVMAX of
the primary tumour.
Keywords Head and neck cancer.FDG PET scan.Target
volume delineation.Radiation treatment outcome.
Functional imaging
Introduction
In head and neck cancer various treatment strategies have
been developed to improve outcome. However, it remains
difficult to select patients for these intensified treatments
despite careful evaluation of clinical factors such as tumour
size/stage, lymph node involvement and anatomic subsite.
Therefore, identification of novel pretreatment factors that
potentially predict treatment response and long-term out-
come is of great interest [1]. The development of molecular
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study of the pathophysiology of cancers.
In head and neck cancer there are indications that
pretreatment tumour
18F-fluorodeoxyglucose (FDG) uptake
may be an independent prognostic factor [1]. Many
research groups have studied the incorporation of FDG
PET into radiation treatment planning, and several ways of
using PET data have been described. Visual interpretation is
the most commonly used method [2–5]. This method,
however, is susceptible to variations due to the window
level settings of the images and is highly operator-
dependent. Therefore, more objective methods have been
explored. Examples are isocontouring based on a standard-
ized uptake value (SUV) of 2.5 around the tumour [3, 6–8],
a fixed threshold of the maximum signal intensity [9–13],
or a threshold which is adaptive to the signal to background
ratio (SBR) [3, 14]. We recently demonstrated that FDG
PET may have important consequences for the definition of
the gross tumour volume (GTV) of the primary tumour in
head and neck cancer, and that the choice of the PET
segmentation tool is not trivial [15]. The aim of this study
was to assess the prognostic value of the determination of
primary tumour volume from CT and FDG PET scans, and
various ways of quantifying FDG uptake in patients with
head and neck cancer treated with (chemo)radiotherapy,
and to provide an overview of the available literature.
Material and methods
Patients
A total of 77 patients (58 men and 19 women; median age
61 years, range 43–86 years) with stage II–IV squamous
cell carcinoma of the head and neck area, eligible for
primary curative radiotherapy, were prospectively enrolled
from June 2003 until July 2006. FDG PET was performed
only for research purposes, and did not influence treatment.
The tumour characteristics are summarized in Table 1.N o
information on human papillomavirus relatedness can be
provided. The study was approved by the Ethics Committee
of the Radboud University Nijmegen Medical Centre and
all patients provided informed consent.
Treatment
All patients were discussed in a multidisciplinary confer-
ence for tumour classification and treatment recommenda-
tions. Our protocol recommended treating primary tumour
and metastatic lymph nodes to a dose of 68–70 Gy This
was combined with concomitant weekly intravenous cis-
platinum 40 mg/m
2 for large unresectable tumours. Elective
lymph node regions were treated to 44 Gy.
Image acquisition
Before treatment, a CT scan and an FDG PET scan were
acquired in radiation treatment position with the patient
immobilized using a custom-made rigid mask covering the
head, neck and shoulders. Maximum reproducibility in
positioning was ensured by the use of additional support
systems: a flat scanning bed, customized head support
cushion, intraoral mould when indicated, standard cushion
supporting the knees, and laser positioning system as
previously described [15]. CT scans were acquired using a
multislice spiral CT scanner (Philips AcQsim; Philips,
Cleveland, OH). Scanning parameters were 130 kV, 120
mAs, slice distance and slice thickness 3 mm, scanning the
head and neck area, with intravenous contrast agent. FDG
PET scans were acquired using a full-ring dedicated PET
scanner (Siemens ECAT Exact 47; Siemens/CTI, Knox-
ville, TN). Patients with diabetes mellitus were not
excluded. However, glucose levels had to be appropriately
regulated (glucose level at time of FDG injection
<10 mmol/l, no insulin administration before FDG injec-
tion). A 3-D emission scan of the head and neck area and a
2-D
68GE-based transmission scan for attenuation correc-
tion were acquired 60 min (median±SD 64±11.4 min) after
Tumour
characteristic
No. of
patients
Site
Oral cavity 6
Oropharynx 30
Hypopharynx 9
Larynx 32
T stage
T1 1
T2 15
T3 39
T4 22
N stage
N0 21
N1 10
N2a 0
N2b 17
N2c 28
N3 1
Histological
grade
14
23 7
33 3
Unknown 3
Total 77
Table 1 Tumour characteristics
of 77 patients
1450 Eur J Nucl Med Mol Imaging (2011) 38:1449–1458intravenous injection of 250 MBq FDG (Covidien, Petten,
The Netherlands). The acquisition time per bed position
was 5 min for emission and 3 min for the Ge-based
transmission scan, resulting in a total scanning time of
16 min for the two bed positions. Image reconstruction has
been described in detail previously [16].
Three-dimensional surface models were automatically
derived from both the CT and PET images. These models
were anatomically coregistered using an operator-
independent iterative closest point algorithm, with an
average registration error of 2.0 mm at the centre of the
planning area as described previously [17]. SUV was
defined as the voxel value of detected activity multiplied
by the weight of the patient divided by the activity at the
beginning of the scan.
The CT and the two PET datasets were transferred via
DICOM to a Pinnacle
3 treatment planning system (Philips
Medical Systems, Andover, MA) for target volume definition.
Target volume definition
The primary tumour was delineated on CT and FDG PET
images by two experienced radiation oncologists in consen-
sus. The volume of the metastatic lymph nodes was not
included.TheroleofFDGPETinthedelineationofmetastatic
lymph nodes has been analysed previously [18].
On CT images, the GTV (GTVCT) was delineated
manually according to current clinical protocols using
information gathered from physical examination, available
diagnostic work-up imaging (CT and/or MRI, examination
under general anaesthesia) and the CT scan in treatment
position. When the radiation oncologists were drawing the
GTVCT contours, the FDG PET images were blinded.
Five PET-based volumes were obtained using different
delineationapproaches.The volumes weredelineatedvisually
(PETVIS) by contouring the FDG activity that was clearly
above normal background activity. Locations with increased
FDG uptake were classified as malignant in consensus with
an experienced nuclear medicine physician. The other
(threshold-based) volumes were obtained using in-house
developed software scripts for the Pinnacle
3 treatment
planning system. Volumes were delineated by applying an
isocontour of SUV=2.5 (PET2.5) around the tumour.
Volumes were delineated using two fixed percentage thresh-
olds of 40% (PET40%) and 50% (PET50%) of the maximum
signal intensity in the primary tumour (SUVMAX). Finally,
volumes were delineated using an adaptive threshold based
on the SBR (PETSBR), as developed at Université St. Luc in
Brussels, Belgium [14]. Calibration and implementation of
the PETSBR method have been described in detail previously
[15]. Results obtained by automated delineation algorithms
were checked visually before acceptance. A delineation was
considered unsuccessful if the resulting volume included
significant volumes of tissue that were clearly normal on
visual interpretation.
The mean FDG uptake of each PET-based volume was
recorded (SUVmeanVIS,S U V mean2.5,S U V mean40%, SUV-
mean50%, SUVmeanSBR). This was multiplied by the
corresponding volume resulting in the integrated SUV
(iSUVVIS, iSUV2.5, iSUV40%, iSUV50%, iSUVSBR).
Treatment outcome analysis
Follow-up visits included history, inspection of the upper
aerodigestive tract and palpation of the neck. Local and
regional recurrences were proven by histology and cytolo-
gy, respectively. Distant metastases were identified by
either pathologically or radiologically.
Statistics
All statistical analyses were performed using SPSS version
16.0 (SPSS, Chicago, IL). The significances of differences
between two categories were established using t-tests or
Mann-Whitney U testing, when appropriate. The normality
of distributions were assessed using Kolmogorov-Smirnov
tests. Variables were entered as continuous variables in Cox
regression analyses to avoid the need to establish a cut-off
value for local control (LC), regional recurrence-free survival
(RRFS), distant metastasis-free survival (DMFS), disease-
free survival (DFS) and overall survival (OS). A p<0.05was
a priori considered as statistically significant.
Results
Tumour volume measurements
For CT-based primary tumour volume measurements, 77
datasets were available. PETVIS was generated for all 77
patients; the PETSBR segmentation tool resulted in unsuc-
cessful volume definition in two patients. A delineation was
considered unsuccessful if the resulting GTV included
significant volumes of tissue that were clearly normal on
visual interpretation. This was observed in four patients for
both PET40% and PET50%, two of whom also had an
unsatisfactory PETSBR.T h eP E T 2.5 segmentation tool was
unsuccessful in 35 patients, including the four patients
mentioned. As a consequence, this latter method was not
evaluated further. All unsuccessful volume definitions were
largely over-sized, being at least 300 cm
3 and clearly
incorporated benign tissue. An unsuccessful delineation did
not correlate with specific tumour subsite or T stage. An
example of an inadequate PET2.5 is shown in Fig. 1.T h e
mean absolute tumour volume for the various methods were
22.7, 21.5, 16.4, 10.5 and 11.2 cm
3 for GTVCT,P E T VIS,
Eur J Nucl Med Mol Imaging (2011) 38:1449–1458 1451PET40%,P E T 50% and PETSBR,r e s p e c t i v e l y .G T V CT and
PETVIS yielded similar mean absolute volumes, but the
threshold-based methods (PET40%,P E T 50% and PETSBR)
yielded volumes that were all smaller than GTVCT (p≤0.0001
for all comparisons). Overlap and mismatch analyses per-
formed in order to evaluate the location of the acquired
volumes showed that in 64%, 59%, 29% and 31% of the
PETVIS,P E T 40%,P E T 50% and PETSBR volumes, respectively,
more than 20% of the volume was located outside the GTVCT
domain.
Treatment and treatment outcome
The median primary tumour radiation dose was 68 Gy
(range 64–72 Gy). Three patients were not treated; one died
just prior to radiotherapy, another refused primary radio-
therapy, and the third developed distant metastases prior to
radiotherapy. After a median follow-up of 46 months (range
2.5–76 months), LC, RRFS, DMFS, DFS and OS at 2 years
were 84%, 95%, 86%, 73% and 77%, respectively. Follow-
up was at least 24 months or until the patient’s death. After
primary treatment, five patients did not achieve complete
remission. These patients did not have significantly
different CT- or PET-based tumour volumes from the
patients who did achieve complete remission. No recur-
rences were seen in the areas treated with an elective dose.
Prognostic value of CT and PET
Primary tumour volume (PET- or CT-based), SUVmean,
SUVMAX and iSUV were not able to predict the likelihood
of complete remission. The CT- and PET-based tumour
volumes of the patients who did achieve complete
remission (n=69) are shown in Fig. 2.T h e r ew a sa
significant difference in the volumes of oral cavity and
oropharyngeal tumours as compared to laryngeal and
hypopharyngeal tumours (p≤0.004, Mann-Whitney). The
values of SUVMAX for oral cavity/oropharyngeal tumours
and laryngeal/hypopharyngeal tumours were 9.7 and 10.0,
respectively. We analysed LC, RRFS, DMFS, DFS and OS
in the 69 patients who achieved complete remission after
primary treatment using primary tumour volume (PET- or
CT-based), SUVmean, SUVMAX and iSUV as continuous
variables in Cox regression survival analyses.
In hypopharyngeal and laryngeal tumours, none of the
CT or PET parameters was associated with any of the
Fig. 1 Planning CT image (a), corresponding FDG PET image (b)
and fusion image (c) in a patient with T3N2bM0 oropharyngeal
carcinoma show differences in target volume definition. Indicated are
GTV delineated on the CT image (GTVCT; red, absolute volume of
34.0 cm
3) and PET-based GTVs obtained by visual interpretation
(PETVIS; light green, volume 33.8 cm
3), applying an SUV isocontour
of 2.5 (PET2.5; orange), using a fixed threshold of 40% (PET40%;
yellow, volume 14.0 cm
3) and 50% (PET50%; blue, volume 13.4 cm
3)
of the maximum signal intensity, and applying an adaptive threshold
based on the SBR (PETSBR; dark green, volume 15.0 cm
3). GTV2.5
was unsuccessful in this patient because of inclusion of large areas of
normal background tissue. Note that on this transverse slice PET50%
and PETSBR are indistinguishable
Fig. 2 Box and whisker plot showing 5% and 95% confidence
intervals (whiskers), 25% and 75% confidence intervals (boxes), and
median of CT- and PET-based tumour volumes of oral cavity/
oropharyngeal tumours (unfilled boxes) and hypopharyngeal/laryngeal
tumours (filled boxes). There was a significant difference in the
volumes of oral cavity and oropharyngeal tumours as compared to
laryngeal and hypopharyngeal tumours (p≤0.004, Mann-Whitney)
1452 Eur J Nucl Med Mol Imaging (2011) 38:1449–1458outcome-related endpoints. SUVMAX and SUVmean also had
no prognostic value in oral cavity and oropharyngeal
tumours. The other results for oral cavity and oropharyn-
geal tumours are presented in Table 2. In these head and
neck subsites, PETVIS was able to predict LC, whereas the
other volume-based methods were not. Both PETVIS and
GTVCT were able to predict DMFS, DFS and OS.
Furthermore, all iSUV methods were able to predict LC,
DMFS, DFS, and OS, albeit sometimes with borderline
significance (p-values between 0.051 and 0.055). Figure 3
shows individual data points of GTVCT and PETVIS in
relation to LC and DFS of oral cavity/oropharyngeal
tumours with a follow-up of at least 24 months. Although
the mean values differed significantly, Fig. 3 also shows
that there was a large overlap in the volume range between
patients with and without recurrence or death, indicating
that the discriminative power of GTVCT and PETVIS is
limited.
Discussion
In this study we assessed the prognostic value of CT- and
FDG PET-based primary tumour volume measurements,
mean FDG uptake (SUVmean) and maximum FDG uptake
(SUVMAX), and iSUV in a large cohort of patients with
head-and-neck cancer treated with (chemo)radiotherapy.
Interestingly, PETVIS was able to predict LC of oral
cavity and oropharyngeal tumours, but GTVCT was not,
while the mean PETVIS and GTVCT volumes were similar.
Other studies have confirmed the lack of prognostic
potential of CT-based primary tumour volume in oral cavity
and oropharyngeal tumours [33, 34]. Our observation that
PETVIS is associated with LC is novel. It remains
questionable, however, if visual assessment can be a
reliable prognostic tool given the operator-dependent nature
of this method. Both GTVCT and PETVIS were able to
predict DMFS, DFS and OS in these subsites. For CT-based
primary tumour volume this was also observed by Chao et
al. in 31 patients with oropharyngeal cancer treated with
definitive (chemo)radiotherapy [35]. Apparently, in oro-
pharynx tumours local radiotherapy response does not
depend so much on the primary tumour volume, but
possibly more on the biological characteristics of the
tumour [36]. On the other hand, these results do suggest
that metastatic potential is associated with the primary
tumour volume in this head and neck subsite. One other
study of 59 patients with stage III–IV head and neck cancer
treated with definitive (chemo)radiotherapy found a corre-
lation between PET-based primary tumour volume, using
the PET2.5 method, and PFS [28]. After further analyses the
study also showed that a volume ≥9.3 cm
3 was associated
with a decreased OS.
All the iSUV methods (the product of the PET-based
primary tumour volume and the SUVmean within that
volume, reflecting the metabolic volumes) were able to
predict LC, DMFS, DFS and OS in oral cavity and
oropharynx tumours, albeit sometimes with borderline
significance. iSUV is a new variable fully representing the
total metabolic activity within a predefined tumour volume.
La et al. also found a correlation between iSUV and
treatment outcome, albeit based on cumulative volumes of
both the primary tumour and the PET-avid lymph nodes
[27]. However, they hypothesized that the effect was due to
the volume and not the product of volume and SUVmean.I n
contrast, our data indicate that of all the PET-based volume
measurements, only PETVIS had a predictive value, while
this was the case for practically all the iSUV methods. This
suggests that the product of volume and SUVmean provides
a more robust parameter which could possibly be a
surrogate for both tumour aggressiveness and the total
cancer cell mass.
In hypopharyngeal and laryngeal tumours we found no
association between GTVCT or PETVIS and treatment
outcome, whereas several studies have demonstrated the
prognostic value of CT-determined tumour volume for
outcome after definitive radiation therapy for these subsites
as well as for nasopharyngeal cancer [37]. We do not have a
solid explanation for this observation, except for the fact
that we obtained high tumour control rates (LC at 2 years of
86%) compared to several other studies, and consequently
relatively few events which would reduce the discrimina-
Table 2 Primary tumour volume (PET- or CT-based) and PET-based
iSUVas variables in treatment outcome prediction in patients with oral
cavityandoropharynxtumourswhoachievedcompleteremission(n=31)
after definitive (chemo)radiotherapy. Variables were assessed using Cox
regression analysis. The values shown are p-values
Outcome GTVCT PETVIS PET40% PET50% PETSBR iSUVVIS iSUV40% iSUV50% iSUVSBR
LC >0.1 0.031 >0.1 >0.1 >0.1 0.021 0.025 0.039 0.033
RRFS >0.1 >0.1 >0.1 >0.1 >0.1 >0.1 >0.1 >0.1 >0.1
DMFS 0.003 0.046 0.080 0.064 >0.1 0.055 0.023 0.023 0.024
DFS 0.024 0.016 >0.1 >0.1 >0.1 0.033 0.041 0.054 0.051
OS 0.018 0.023 >0.1 >0.1 >0.1 0.026 0.038 0.052 0.040
Eur J Nucl Med Mol Imaging (2011) 38:1449–1458 1453tive power of any pretreatment test. None of the three
semiquantitative methods for PET-based tumour volume
calculation (PET40%, PET50% and PETSBR) showed an
association with outcome in any of the head and neck
subsites. It should be noted that all three semiquantitative
methods produced significantly smaller variability. This
may also reduce discriminative power.
As the absolute volumes of FDG PET-based tumour
sometimes partly located outside the GTVCT domain were
small, it was not possible to determine whether the exact
origin of a recurrence lay located outside the GTVCT
domain, but within the FDG PET-based tumour volume.
In our cohort the SUVMAX of the primary tumour was not
able to predict radiation treatment outcome. Table 3 summa-
rizes the results of a literature search for studies examining
the role of pretreatment FDG PET SUVMAX in patients with
head and neck cancer treated with definitive (chemo)
radiotherapy in predicting outcome. Of 15 studies identified,
8s h o w e dt h a tS U V MAX could possibly play a role in
predicting radiation treatment response [1, 19–25]a n d7
showed that it does not [26–32]. These inconsistencies
could be a result of the heterogeneity of treatment modalities,
the heterogeneity of tumour sites, the use of several endpoints
(i.e. LC, LRF, DFS or OS), the use of various SUVMAX cut-
off values, and the use of either the SUVMAX of the primary
tumour or the SUVMAX of a metastatic lymph node. It is
important to note that of the eight studies demonstrating an
association between SUVMAX and outcome, six included
substantial numbers of patients who were treated with
surgery. Overall, of the 408 patients included in these six
studies, 227 (55%) underwent primary surgery. In fact, the
study by Brun et al. is the only one indicating that SUVMAX
is a prognostic factor in a population treated with definitive
(chemo)radiotherapy alone, and using only the SUVMAX of
the primary tumour, finding that DFS and OS were worse
when SUVMAX was >9.0 [19]. Thus, based on this overview
of the literature, an unequivocal conclusion about the
predictive role of pretreatment FDG PET SUVMAX in
patients with head and neck cancer treated with definitive
(chemo)radiotherapy cannot yet be drawn. Possibly a studies
of larger cohorts of patients with homogeneous tumours and
treatment characteristics stratified for the various subsites
would be able to establish a role for a SUVMAX cut-off value
in order to investigate future treatment individualization.
Ideally these studies should use the same type of treatment
and the same definition of treatment outcome.
Using pretreatment primary tumour volume based on
FDG PET is appealing, and has not yet been extensively
reported. In the current study, PETVIS proved to be the only
PET-based volume able to predict treatment outcome, and
only in the oral cavity and oropharyngeal tumours. It
should be noted that the discriminative potential of PETVIS
may be limited because of the large overlap between data
points of patients with and without recurrence. The
volumes generated by semiautomated PET segmentation
methods were not useful for outcome prediction.
Thorwarth et al. demonstrated that cumulative FDG
PET-based volumes of both the primary tumour and the
PET-avid lymph nodes could not predict treatment outcome
in a small series of patients with head and neck cancer
treated with definitive (chemo)radiotherapy [31]. They
generated the PET-based volume by encompassing all
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Eur J Nucl Med Mol Imaging (2011) 38:1449–1458 1455voxels showing a higher intensity than 40% of the
maximum value. La et al. showed a correlation between
DFS and OS of 85 patients with head and neck cancer
treated with definitive (chemo)radiotherapy and the FDG
PET-based cumulative volumes of both the primary tumour
and the PET-avid lymph nodes [27]. They generated the
PET-based volume by encompassing all voxels showing a
higher intensity than 50% of the maximum value. Recently,
Chung et al. showed a correlation between the DFS of 82
patients with pharyngeal cancer treated with definitive
(chemo)radiotherapy and the FDG PET-based cumulative
volumes of both the primary tumour and the PET-avid lymph
nodes [26]. They generated the PET-based volume by
encompassing all voxels showing an SUV of ≥2.5, and this
was significant prognostic factor for DFS, whereas stage,
histological grade and SUVMAX were not. In our cohort, the
PET2.5 segmentation method resulted in an unsuccessful
delineation in 35 patients, and factors that might explain this
finding have been addressed in a previous report [15].
The use of a molecular imaging modality such as FDG
PET to identify a robust variable on which prediction of
treatment response and long-term outcome can be based
remains attractive. Thus far, there is no role for pretreatment
FDG PET as a predictor of outcome in head and neck
cancer in daily routine, given the inconsistencies between
studies and the low levels of evidence. However, this
potential application of FDG PET needs further explora-
tion, focusing both on FDG PET-based primary tumour
volume and on iSUV and SUVMAX of the primary tumour.
Preferably these questions should be incorporated in
prospective phase III trials with strict criteria on treatment
and outcome parameters. Other research questions are
worth considering such as adding the data of a repeat
FDG PET scan during treatment to the data acquired by a
pretreatment FDG PET scan, and the use of different PET
tracers such as
18F-fluoromisonidazole and 3′-deoxy-3′-
18F-
fluorothymidine, to image hypoxia and tumour cell prolif-
eration, respectively, which are well-known tumour char-
acteristics relevant to radiation response [38].
Conclusion
There are three major findings of this study. First, in oral
cavity and oropharyngeal tumours PETVIS was the only
volume-based method able to predict LC. Both PETVIS and
GTVCT were associated with DMFS, DFS and OS in these
subsites. Second, in oral cavity and oropharyngeal tumours
the volume- and SUV-derived parameters iSUVVIS,
iSUV40%, iSUV50%, iSUVSBR were consistently associated
with LC, DMFS, DFS and OS, while SUVmean and
SUVMAX were not. Third, in hypopharyngeal and laryngeal
tumours, none of the CT and PET parameters was
correlated with treatment outcome.
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1456 Eur J Nucl Med Mol Imaging (2011) 38:1449–1458Given the inconsistencies between studies and low level
of evidence thus far, there is no role yet for pretreatment
FDG PET as a predictor of outcome in head and neck
cancer in daily routine. Due to the heterogeneous nature of
head and neck cancers, the difficulty in obtaining a large
number of patients, and the variation in results, one has to
be careful interpreting the results from our and similar
studies, as they are based on a relatively low number of
events. However, this potential application of FDG PET
needs further exploration, focusing both on FDG PET-
based primary tumour volume and on iSUV and SUVMAX
of the primary tumour. Preferably these questions should be
incorporated in prospective phase III trials with strict
criteria on treatment and outcome parameters.
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